Toulouse Male Long Term Bed Rest 2001-2002

Centre National d'Etudes Spatiales

Status and phase

Completed

Phase 1

Conditions

Simulation of Weightlessness by Anti-Orthostatic Long Term Bed Rest

Treatments

Behavioral: Physical training

Drug: Ethidronate

Study type

Interventional

Funder types

Other

Identifiers

NCT00311571

MEDES/00-433

Details and patient eligibility

About

Microgravity during space flight induces physiological changes that affect astronauts' health and performance. Space flight simulations such as prolonged bed rest can mimic some of these changes and provide study conditions that are more accessible than during space flight. The European Space Agency, ESA together with the French national space agency, CNES and the Japanese national space agency, NASDA are performing extensive studies using long duration bed rest.

Previous studies including several long and short term bed rest campaigns have yielded significant medical data on the physiological changes induced by space flight. These data can be used to study the effect of countermeasures, methods helping to prevent these physiological changes.

The long duration bed rest, lasting 3 months undertakes a variety of investigations involving 28 subjects. This study focuses on countermeasures, studying the effect of a bone tissue stabilisation medication and resistive exercises to determine their suitability for use during long duration stays on ISS.

The physiological changes recorded during space flight and bed rest mimic those observed in some diseases and in the aging process. Significant clinical applications are expected as a direct result of this experiment and future equivalent studies.

Full description

The spaceflights undertaken to date demonstrated that Man can adapt to the conditions existing in space, particularly to weightlessness. However, the space environment and the prevailing micro-gravity induce modifications which may affect the performances of the astronauts. These modifications concern in particular the cardiovascular and hormonal systems, the muscles, the bones, the blood and the immune system. Other problems may occur during long duration flights, such as the problems created by psychological stress due to the confinement, or those resulting from the cosmic rays (radiation).

In view of the fact that space flight opportunities are few, experiences simulating the effects of weightlessness experiences are undertaken on the earth, in order to better understand the adaptation mechanisms, prepare the spaceflights, perfect and evaluate corrective methods (called counter-measures) such as physical exercise or medication, to facilitate the astronauts' return to base. These experiments are also a necessity, in view of the difficulties encountered when carrying out certain experiences during the flights, due to the presence of too few astronauts on board, and to the lack of advanced biomedical devices onboard (scanner, etc.). The most common simulation is that of the anti-orthostatic bed rest (tilted position with the head slightly under the feet at a -6° angle).

Since the current objective is to simulate flights in the International Space Station (3 to 6 months) or possible flights to Mars (500 to 1000 days), it is mandatory to extend the duration of the simulation experiments. This is why three Space Agencies, CNES (France), European Space Agency (ESA, European Union), National Space Development Agency of Japan (NASDA, Japan) decided to join forces and undertake in common such simulation campaigns on ground, to best apprehend the adaptation processes to the constraints of the space environment.

The 2 main objectives of this experiment are:

to study the physiological changes mechanisms during a ground-based experiment simulating long duration spaceflights,
to develop and validate preventive methods (countermeasures) using standard tests.

This is why we will test in the present study the effects of an orthostatic bed rest (decubitus) of 90 days (3 months) on the following physiological systems :

the bones,
the muscles,
the cardiovascular system and its control mechanisms,
the sleep,
the spine.

In the absence of gravity, the weight of the astronaut and that of the objects disappear completely. This induces modifications of the bones and the muscles which can severely affect the astronaut's life during the flight, and even more when returning to earth. This is a fundamental point to study, since it may become a limiting factor and even an obstacle to long duration flights. This experiment should also permit the test of physical exercise program and of a drug, pamidronate (AREDIA®), as counter-measures against the effects of weightlessness on the locomotion system (skeleton and muscles).

A total of 28 volunteers will participate to this experiment, split into three groups. Said experiment will spread on 2 years, 14 volunteers participating each time. The 3 groups are the following:

Group "physical exercise" (9 volunteers),
Group "drug" (pamidronate) (9 volunteers),
Group "control" (10 volunteers).

Members of the groups will be drawn by lot among the participants

Group "Exercise" : exposure of Man to microgravity results in a muscular atrophy which affects the muscles of the lumbar region and those of the lower limbs which are concerned by the standing position and the locomotion. During certain flights, physical exercise programs have been implemented, in order to fight against this muscular atrophy, maintain the physical condition required for the mission and prepare the astronauts for their return on earth. In the course of the present experiment, a physical exercise program will be tested on the 9 volunteers of this group (resistance training using both calf and knee extensor muscles with a special devicecalled Fly-Wheel).
Group "Drug" : a Man in microgravity is the sole experimental model available to test the rapid occurrence of osteoporosis on a healthy subject. Osteoporosis, or porous bone, appears whenever the rate at which the bone material is replaced falls below that of resorption, thus creating a bone fragility and an increased risk of fracture (hip, spine and wrist essentially). It appears generally after menopause, when associated with aging and a lack of physical activity. The pamidronate (Aredia®) is a drug present on the market since many years, used for the treatment of several bone pathologies. This drug will be tested on the 9 volunteers of this group, to demonstrate its efficiency in treating of bone modifications. This drug (60mg) will be infused intravenously 14 days before bed rest.
Group "control" : this group will serve as reference for the experimentation. Volunteers in this group will be without physical exercise and without drug. The existence of this group is necessary to be able to compare the results of the 2 types of counter-measures.

The experience will be carried out during a 120 days stay (a total of 4 months) at the Space Clinic and will comprise:

1 control ambulatory period of 15 days (subjects to report on day before) (-15 at -1),
1 anti-orthostatic (-6°) bed rest period of 90 days (1 at 90),
1 recovery ambulatory period of 15 days (subjects to depart the following morning) (+1 at +15), representing a total of 122 nights spent at the clinic for all volunteers.

The assessments will be done by different European and Japanese scientific teams,each one specialising in a specific domain. None of the 3 groups of volunteers will be submitted to all experimentation programs.

Sex

Male

Ages

25 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Healthy male volunteer , citizen of the European Community.
Age 25 to 45,
Non smokers,
No alcohol, no drug dependence and no medical treatment,
Height 165 cm to 185 cm,
No overweight nor excessive thinness. BMI (weight Kg/ height m2) between 20 and 27,
No personal nor family past record of chronic or acute disease which could affect the physiological data and/or create a risk for the subject during the experiment,
Subject to be covered by a Social Security system,
Free of any engagement during four consecutive months.

Exclusion criteria

Having given blood (more than 300ml) in a period of three months or less before the start of the experiment,
Subject already participating in a clinical research experimentation,
Poor tolerance to blood sampling,
Past record of orthostatic intolerance,
Cardiac rhythm disorders,
Allergies,
Intensive sport training,
Fractures or tendon laceration since less than one year,
Chronic back pains,
Past records of thrombophlebitis,
Presence of metallic implants,
Special food diet,
Sleep disorders :Lark and owl type,Subject sleeping more than 10 hours or less than 5 hours,
Photosensitive epilepsy.